Wrapmanager Inc. Purchases Shares of 20,611 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wrapmanager Inc. acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 20,611 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Amicus Therapeutics during the 1st quarter worth approximately $291,000. Sei Investments Co. lifted its position in shares of Amicus Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 222,715 shares of the biopharmaceutical company’s stock worth $2,624,000 after purchasing an additional 19,366 shares during the last quarter. American International Group Inc. grew its stake in shares of Amicus Therapeutics by 1.3% during the first quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after purchasing an additional 1,785 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Amicus Therapeutics by 7.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after buying an additional 7,304 shares during the last quarter. Finally, EntryPoint Capital LLC increased its holdings in Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 9,729 shares during the last quarter.

Amicus Therapeutics Trading Down 1.4 %

Shares of FOLD stock opened at $9.52 on Wednesday. The company has a market capitalization of $2.84 billion, a P/E ratio of -28.00 and a beta of 0.68. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The business’s 50 day moving average is $10.92 and its two-hundred day moving average is $10.60. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Cantor Fitzgerald upped their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Finally, Morgan Stanley dropped their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. The trade was a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 30,401 shares of company stock valued at $352,038 over the last three months. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.